Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus

International Journal of Antimicrobial Agents

Volumn 39, Issue 2, 2012, Pages 159-162

  Arhin, Francis F ^a   Sarmiento, Ingrid ^a   Parr Jr , Thomas R ^a   Moeck, Gregory ^a  

^a Medicines Company   (Canada)

Author keywords

Inoculum effect; Lipoglycopeptide; Resistance trends

Indexed keywords

ANTIBIOTIC AGENT; DAPTOMYCIN; LINEZOLID; METICILLIN; ORITAVANCIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BROTH DILUTION; CELL DENSITY; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; IN VITRO STUDY; INOCULATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; GLYCOPEPTIDES; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; STAPHYLOCOCCUS AUREUS; TIME FACTORS;

EID: 84855515382     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.09.017     Document Type: Article

References (15)

1. McKay GA, Beaulieu S, Arhin FF, Belley A, Sarmiento I, Parr Jr TR, et al. Time - kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 2009;63:1191-9.
2. Bhavnani SM, Lehoux D, Rubino CM, Moeck G, Okusanya OO, Forest A, et al. Use of pharmacokinetics - pharmacodynamics to support oritavancin dose selection for patients with complicated skin and skin structure infections: proof of concept. In: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICCAC). Washington, DC: ASM Press; 2009 [Abstract A1-1228].
3. Dunbar LM, Milata J, McClure T, Wasilewski MM; the SIMPLIFI Study Team. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob Agents Chemother 2011;55:3476-84.
4. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004;48:4665-72. (Pubitemid 39577670)
5. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. Document M7-A8. Wayne, PA: CLSI; 2009.
6. Arhin FF, Belley A, McKay GA, Beaulieu S, Sarmiento I, Parr Jr TR, et al. Assessment of oritavancin serum protein binding across species. Antimicrob Agents Chemother 2010;54:3481-3.
7. National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. Document M26-A. Wayne, PA: NCCLS; 1999.
8. Mercier R-C, Houlihan HH, Rybak MJ. Pharmacodynamic evaluation of a new glycopeptide, LY33328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium. Antimicrob Agents Chemother 1997;41:1307-12. (Pubitemid 27231432)
9. Arhin FF, Sarmiento I, Parr Jr TR, Moeck G. Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin. J Antimicrob Chemother 2009;64:868-70.
10. Arhin FF, Draghi DC, Pillar CM, Parr Jr TR, Moeck G, Sahm DF. Comparative in vitro activity profile of oritavancin against recent Gram-positive clinical isolates. Antimicrob Agents Chemother 2009;11:4762-71.
11. Kim SJ, Singh M, Dietrich E, Far AR, Schaefer J. Mechanism of glycopeptide resistance in Mu50, a Staphylococcus aureus strain with intermediate glycopeptide resistance, by solid-state NMR. In: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICCAC). Washington, DC: ASM Press; 2009 [Abstract C1-1357].
12. Watanabe Y, Neoh H-M, Cui L, Hiramatsu K. Improved antimicrobial activity of linezolid against vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2008;52:4207-8.
13. Leonard SN, Szeto YG, Zolotarev M, Grigoryan IV. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA). Int J Antimicrob Agents 2011;37:558-61.
14. Turco GF, Melko GP, Williams JR. Vancomycin-intermediate resistant Staphylococcus aureus. Ann Pharmacother 1998;32:758-60.
15. Nadrah K, Strle F. Antibiotic combinations with daptomycin for treatment of Staphylococcus aureus infections. Chemother Res Pract 2011, doi:10.1155/2011/619321.